The short version.
Women in their 40s often describe a constellation: energy that doesn't recover the way it used to, sleep that's lighter and more interrupted, cognitive change (the "brain fog" that's both a real symptom and a frustratingly vague one), and shifts in body composition. The dominant biology behind that constellation is hormonal — declining estrogen, fluctuating progesterone, and the cascade those changes trigger.
NAD+ sits adjacent to that picture. Mitochondrial function, sirtuin activity, and cellular energetics are all touched by both estrogen status and NAD+ levels. NAD+ is one tool that can be considered alongside — not instead of — a proper hormonal evaluation.
What the literature actually says.
The strongest evidence for women over 40 lives in two adjacent literatures: the broader NAD+/aging research (mostly aging-general, not female-specific) and the menopause/HRT research (well-established, with strong RCT data for hot flashes, bone density, and cardiovascular outcomes). The intersection — randomized trials of NAD+ specifically in perimenopausal women — is thin.
What we do know: estrogen modulates mitochondrial function, including NAD+ metabolism. The drop in estrogen during the menopausal transition correlates with changes in mitochondrial efficiency. Whether replacing NAD+ alone produces a meaningful subjective change in this population is exactly the kind of question that hasn't been answered with a clean trial.
The honest framing: if you're a woman in her 40s with the symptoms above, the highest-yield first conversation is usually about hormones, sleep architecture, and metabolic labs — not NAD+. NAD+ can be part of a thoughtful program, but it's not a substitute for getting the hormonal picture characterized.
The first conversation for a woman in her 40s is usually about hormones, not NAD+.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Have we characterized hormones (estradiol, progesterone, FSH, thyroid) before adding NAD+?
- Are sleep architecture and iron studies on the table — they often explain a lot?
- If we add NAD+, what's the timeframe before we evaluate response?
- Does HRT (where appropriate) sequence before NAD+ in our plan?
- How do we tell what's hormonal vs metabolic vs cellular?
Sources